 |
|
|
| |
Final evaluation of HCV patients treated with 12 week
regimens containing sofosbuvir +/- simeprevir in the TRIO network:
academic and community treatment of a real-world, heterogeneous population
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Douglas Dieterich1, Bruce Bacon2, Steven Flamm3, Kris Kowdley4, Scott Milligan5, Naoky Tsai6, Zobair Younossi7 and Eric Lawitz8
1Icahn School of Medicine at Mount Sinai, 2Saint Louis University School of Medicine, 3Northwestern University Feinberg School of Medicine, 4Liver Care Network, Swedish Medical Center, Seattle, WA, 5Trio Health Analytics, 6Queens Medical Center, University of Hawaii, 7Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 8The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX
|
| |
|
|
|
|
|
